Polycystic ovarian syndrome (PCOS), recently referred also as hyperandrogenic anovulation, is a chronic anovulation syndrome associated with androgen excess.
The Rotterdam criteria is used to make the diagnosis of PCOS and require any two of the following three criteria for the diagnosis, as well as the exclusion of other etiologies (e.g. congenital adrenal hyperplasia, Cushing syndrome, and/or an androgen-secreting tumor) 4,18:
ovulatory dysfunction (oligo- and/or anovulation)
clinical and/or biochemical signs of hyperandrogenism
polycystic ovarian morphology on ultrasound
Hence, ultrasound is not necessary for the diagnosis if features of both ovulatory dysfunction and hyperandrogenism are present, but will identify the complete PCOS phenotype.
More recently an International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome is also been published 23.
On this page:
Terminology
"Hyperandrogenic anovulation" has been proposed as a more accurate and potentially less confusing term, as the ovarian feature is of multiple follicles and not cysts 13. At this stage, however, "polycystic ovarian syndrome" remains the term that is widely known and used.
Epidemiology
The estimated prevalence is 8-13% of women of reproductive age but this varies (up to 20%) depending on the diagnostic criteria used 11.
Associations
subfertility and recurrent pregnancy loss
-
long-term increased risk of
type 2 diabetes mellitus
dyslipidemia
cardiovascular disease
endometrial cancer (two to six-fold increased risk) 6,18
high prevalence of anxiety and depression
women with polycystic ovarian morphology are at increased risk of OHSS when undergoing IVF, regardless of whether they have PCOS 15
Clinical presentation
The classic triad of PCOS is:
oligomenorrhea and/or anovulation
hirsutism
obesity
In addition to this, patients may have infertility, acne, alopecia or biochemically show increased androgen levels.
Pathology
Markers
Biochemical hyperandrogenism is based on the measurement of free testosterone, free androgen index, or calculated bioavailable testosterone, androstenedione and dehydroepiandrosterone sulphate 20.
Anti-Müllerian hormone (AMH) levels are generally increased, and there is emerging evidence for the utility of AMH in the diagnosis of PCOS. At the time of writing, there is insufficient assay standardization and validation, and AMH should not be used in the diagnosis of PCOS at this stage 18.
Radiographic features
Ultrasound
Ovaries may be normal in PCOS, and conversely, polycystic ovarian morphology (PCOM) may be seen in women without the syndrome. However, it is well accepted that women with PCOS tend to have larger ovaries with an increased number of follicles.
The specific diagnostic cut-offs, however, have been the subject of debate and revision in recent years. The updated diagnostic criteria at the time of review are based on a 2018 international consensus guideline 18.
In patients >8 years post menarche, and using a high-frequency endovaginal probe:
follicle number per ovary (FNPO) ≥20, and/or
ovarian volume ≥10 mL, ensuring no corpora lutea, cysts or dominant follicles are present
If using transabdominal scanning, or older technology where ovarian morphology is not well visualized, consider using the ovarian volume threshold of ≥10 mL on either ovary.
The diagnostic criteria are adjusted in adolescent females (defined as within 8 years of menarche, or age <20 years) 18, in whom ultrasound should not be used for the diagnosis of PCOS due to the high incidence of multi-follicular ovaries in this life stage 22.
This supersedes the initial Rotterdam criteria of ≥12 follicles and interim recommendations of 24 or 25 follicles per ovary. The presence of a single multifollicular ovary is sufficient to provide the sonographic criterion for PCOS 2.
Other morphological features have been described, but do not contribute to formal diagnostic criteria:
hyperechoic central stroma
peripheral location of follicles (string of pearls sign)
follicles of similar size measuring 2-9 mm
MRI
MRI is not warranted routinely in the investigation of PCOS, nonetheless, pelvic MRI may show most or all of the above sonographic features. Signal characteristics include:
T1: small uniform follicles are low in signal while the central stroma is of intermediate signal (vs normal myometrium)
T2: follicles have high T2 signal while the central stroma is of comparatively low T2 signal 8
History and etymology
The syndrome was first described by I F Stein and M L Leventhal in 1935 7.
Practical points
with a lack of consensus sometimes it is easier to report the number of follicles in each ovary rather than attempt to label the ovaries as "polycystic" or "multifollicular"
ultrasound should not be used for the diagnosis of PCOS in patients <8 years after menarche due to the high incidence of multi-follicular ovaries in this life stage
as the individual age of menarche may not be known, an age cut-off of 20 years is suggested for the utility of ultrasound in this diagnosis (based on the median age at menarche being approximately 12 years)
post menopause, a new or continuing diagnosis of PCOS could be considered based on past history and clinical evidence of persistent hyperandrogenism
postmenopausal women presenting with new-onset, severe or worsening hyperandrogenism including hirsutism, require further investigation to rule out androgen-secreting tumors and ovarian hyperthecosis
Unable to process the form. Check for errors and try again.